Hypercoagulability and Anticoagulation in Patients With COVID-19 Requiring Renal Replacement Therapy

Hypercoagulability and Anticoagulation in Patients With COVID-19 Requiring Renal Replacement Therapy

Bibliographic Details
Main Authors:	Lara N. Roberts, Kate Bramham, Claire C. Sharpe, Roopen Arya
Format:	Article
Language:	English
Published:	Elsevier 2020-09-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024920314236

Similar Items

Mode of Delivery Does Not Influence Postpartum Hypercoagulability Measured by Thrombin Generation or Thromboelastometry
by: Boriana Guimicheva, et al.
Published: (2020-01-01)

Biomarkers of Hypercoagulability in COVID-19
by: Hideo Wada
Published: (2023-05-01)

The Burden of Hypercoagulability in COVID-19
by: Madeleine Kim, et al.
Published: (2022-04-01)

Coagulation System Activation for Targeting of COVID-19: Insights into Anticoagulants, Vaccine-Loaded Nanoparticles, and Hypercoagulability in COVID-19 Vaccines
by: Mohamed S. Abdel-Bakky, et al.
Published: (2022-01-01)

A Case Series of Thromboelastography-Guided Anticoagulation in COVID-19 Patients with Inherited and Acquired Hypercoagulable States
by: Anthony V. Thomas, et al.
Published: (2021-01-01)

Anticoagulation during continuous renal replacement therapy: An update
by: Aslanidis Theodoros, et al.
Published: (2019-01-01)

Thrombophilias: therapeutic employment of direct oral anticoagulants in venous hypercoagulable states
by: Federico Cacciapuoti
Published: (2020-09-01)

Regional citrate anticoagulation for continuous renal replacement therapy in newborns
by: Haixia Huang, et al.
Published: (2023-03-01)

Thrombotic and Hypercoagulability Complications of COVID-19: An Update
by: Shibeeb S, et al.
Published: (2021-08-01)

COVID-19 With Preexisting Hypercoagulability Digestive Disease
by: Mingshan Jiang, et al.
Published: (2021-01-01)

High rate of renal recovery in survivors of COVID-19 associated acute renal failure requiring renal replacement therapy.
by: Jacob S Stevens, et al.
Published: (2020-01-01)

Comparison of different anticoagulation strategies for renal replacement therapy in critically ill patients with COVID-19: a cohort study
by: Frederic Arnold, et al.
Published: (2020-11-01)

Hypercoagulability in Severe COVID Infection
by: Mohammed Fauzi Abdul Rani
Published: (2023-03-01)

Hypercoagulability in critically ill patients with COVID 19, an observational prospective study
by: Laure Calvet, et al.
Published: (2022-01-01)

Hypercoagulability in critically ill patients with COVID 19, an observational prospective study.
by: Laure Calvet, et al.
Published: (2022-01-01)

Angiopoietin-2 Inhibition of Thrombomodulin-Mediated Anticoagulation—A Novel Mechanism That May Contribute to Hypercoagulation in Critically Ill COVID-19 Patients
by: Michael Hultström, et al.
Published: (2022-06-01)

Comparative study of anticoagulation versus saline flushes in continuous renal replacement therapy
by: Nagarik Amit, et al.
Published: (2010-01-01)

Inflammatory and Hypercoagulable Biomarkers and Clinical Outcomes in COVID-19 Patients
by: Hiroki Kitakata, et al.
Published: (2021-07-01)

The pathogenesis of COVID-19: Hypercoagulation and D-dimer in thrombotic complications
by: Leonid DUBEY, et al.
Published: (2023-03-01)

Harmonizing hypercoagulable heterogeneity: Baseline VTE risk in COVID‐19
by: George Goshua, et al.
Published: (2021-01-01)

Regional Citrate Anticoagulation and Systemic Anticoagulation during Pediatric Continuous Renal Replacement Therapy: A Systematic Literature Review
by: Emanuele Buccione, et al.
Published: (2022-05-01)

Hypercoagulability and thrombosis
by: Maria Domenica Cappellini, et al.
Published: (2013-03-01)

Regional citrate anticoagulation for continuous renal replacement therapy in pediatric patients with liver failure.
by: Keila Rodriguez, et al.
Published: (2017-01-01)

Outcomes of patients with COVID-19 requiring extracorporeal membrane oxygenation and continuous renal replacement therapy in the United States
by: Carlos R Franco Palacios, et al.
Published: (2023-08-01)

A case report of COVID-19 complicated with acute kidney injury (AKI) requiring renal replacement therapy
by: Oghenekaro Godwin Egbi, et al.
Published: (2020-11-01)

Letter to the Editor re: Late diagnosis of COVID-19 and hypercoagulable state
by: Rujittika Mungmunpuntipantip, et al.
Published: (2022-06-01)

Sinus venous thrombosis as a complication of COVID-19-associated hypercoagulability
by: Sinda Zarrouk, et al.
Published: (2021-09-01)

Pathogenesis and Treatment Strategies of COVID-19-Related Hypercoagulant and Thrombotic Complications
by: MA Haimei
Published: (2020-07-01)

Regional Citrate Anticoagulation or Heparin Anticoagulation for Renal Replacement Therapy in Patients With Liver Failure: A Systematic Review and Meta-Analysis
by: Wenqian Qi PhD, et al.
Published: (2023-05-01)

Hypercoagulability Evaluation in Antiphospholipid Syndrome without Anticoagulation Treatment with Thrombin Generation Assay: A Preliminary Study
by: Paul Billoir, et al.
Published: (2021-06-01)

Successful Free Tissue Transfer in the Profoundly Hypercoagulable Glioblastoma Multiforme Patient: Surgical Experience and Anticoagulation Protocol
by: Paul A. Niziol, et al.
Published: (2020-07-01)

Is therapeutic anticoagulation improving renal outcomes in COVID-19?
by: Sohaib Roomi, et al.
Published: (2020-07-01)

Anticoagulation practices for continuous renal replacement therapy: a survey of physicians from the United States
by: David Boldt, et al.
Published: (2023-12-01)

Clinical application of regional citrate anticoagulation for continuous renal replacement therapy in children with liver injury
by: Fang Hu, et al.
Published: (2022-10-01)

Filter Size Not the Anticoagulation Method is the Decisive Factor in Continuous Renal Replacement Therapy Circuit Survival
by: Monika Miklaszewska, et al.
Published: (2017-06-01)

Hypercoagulability in multiple myeloma
by: E S Urnova, et al.
Published: (2014-07-01)

Pernio during the COVID-19 pandemic and review of inflammation patterns and mechanisms of hypercoagulability
by: Gregory Cavanagh, BS, et al.
Published: (2020-09-01)

Platelet‐leukocyte interactions in COVID‐19: Contributions to hypercoagulability, inflammation, and disease severity
by: Eugenio D. Hottz, et al.
Published: (2022-03-01)

Letter to the Editor re: Response to late diagnosis of COVID-19 and hypercoagulable state
by: Desdiani Desdiani
Published: (2022-07-01)

The treatment with Jusvinza reduces hyperinflammation and hypercoagulation in critical ill patients with COVID-19
by: Rafael Venegas Rodríguez, et al.
Published: (2021-11-01)